兴齐眼药：SQ-24071滴眼液获得临床试验批准通知书

Group 1 - The core point of the article is that Xingqi Eye Pharmaceutical (300573) has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] - SQ-24071 is classified as a chemical drug of category 2.2; 2.4, indicating it is a modified new drug [1] - The approval signifies a potential advancement in the treatment options available for myopia, a growing concern among younger populations [1]